VENTOLIN SOLUTION FOR INTRAVENOUS INFUSION 5 mg5 ml

Riik: Singapur

keel: inglise

Allikas: HSA (Health Sciences Authority)

Toimeaine:

SALBUTAMOL SULPHATE EQV SALBUTAMOL

Saadav alates:

GLAXOSMITHKLINE PTE LTD

ATC kood:

R03CC02

Annus:

5 mg/5 ml

Ravimvorm:

INJECTION

Koostis:

SALBUTAMOL SULPHATE EQV SALBUTAMOL 5 mg/5 ml

Manustamisviis:

INTRAVENOUS

Retsepti tüüp:

Prescription Only

Valmistatud:

GLAXOSMITHKLINE MANUFACTURING S.p.A

Volitamisolek:

ACTIVE

Loa andmise kuupäev:

1989-04-18

Infovoldik

 
1 

VENTOLIN
 PARENTERAL PREPARATIONS 
SALBUTAMOL 

QUALITATIVE AND QUANTITATIVE COMPOSITION 

Ventolin Injection 500
micrograms (0.5mg), salbutamol, as sulphate, in 1ml (500 micrograms/ml). 
_ _
Ventolin_ _ Solution for Intravenous Infusion 5mg
salbutamol, as sulphate, in 5ml (1mg/ml). 

CLINICAL PARTICULARS

INDICATIONS 

_Respiratory _

Ventolin is a selective 
β
2
 adrenoceptor agonist. At therapeutic doses it acts on the 
β
2

adrenoceptors in the bronchi and uterus, with little or no
action on the 
β
1
 adrenoceptors of the 
heart. It is suitable for the management of an
asthmatic attack, and for uncomplicated premature 
labour, under the direction of a physician. 

Bronchodilators should not be the only or main treatment in
patients with severe or unstable 
asthma. Severe
asthma requires regular medical assessment as death may occur. Patients with 
severe asthma have constant symptoms and
frequent exacerbations, with limited physical 
capacity, and PEF values below 60% predicted at baseline with greater than 30% variability, 
usually not returning entirely to normal after a
bronchodilator. These patients will require high dose 
inhaled (e.g >1mg/day beclomethasone
dipropionate) or oral corticosteroid therapy. Sudden 
worsening of symptoms may require increased
corticosteroid dosage which should be 
administered under urgent medical supervision. 

_VENTOLIN _Injection/Solution for Infusion is indicated for the
relief of severe bronchospasm 
associated with asthma or bronchitis and
for the treatment of status asthmaticus. It is suitable for 
the management of an asthma attack under the direction of a
physician. 

_Obstetric _
_ _
_VENTOLIN _is a selective beta-2
adrenoceptor agonist. At therapeutic doses it acts on the
beta-2 
adrenoceptors in the uterus, with little or no action

Toote omadused

1
VENTOLIN
 PARENTERAL PREPARATIONS
SALBUTAMOL
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ventolin Injection 500 micrograms (0.5mg), salbutamol, as sulphate, in
1ml (500 micrograms/ml).
_ _
Ventolin_ _Solution for Intravenous Infusion 5mg salbutamol, as
sulphate, in 5ml (1mg/ml).
CLINICAL PARTICULARS
INDICATIONS
_Respiratory _
Salbutamol is a selective beta-
2
agonist indicated for the treatment or prevention of bronchospasm.
It provides short acting bronchodilation in reversible airways
obstruction due to asthma, chronic
bronchitis and emphysema.
Bronchodilators should not be the only or main treatment in patients
with persistent asthma. In
patients with persistent asthma unresponsive to _VENTOLIN_, treatment
with inhaled corticosteroids
is recommended to achieve and maintain control. Failing to respond to
treatment with _VENTOLIN _
may signal a need for urgent medical advice or treatment.
_VENTOLIN _Injection/Solution for Infusion is indicated for the relief
of severe bronchospasm
associated with asthma or bronchitis and for the treatment of status
asthmaticus. It is suitable for
the management of an asthma attack under the direction of a physician.
_Obstetric _
_ _
_VENTOLIN _is a selective beta-
2
adrenoceptor agonist. At therapeutic doses it acts on the beta-
2
adrenoceptors in the uterus, with little or no action on the beta-
1
adrenoceptors of the heart. It is
indicated to arrest uncomplicated labour between 22 and 37 weeks of
gestation in patients with no
medical or obstetric contraindication to tocolytic therapy, under the
direction of a physician.
DOSAGE AND ADMINISTRATION
_VENTOLIN _has a duration of action of 4 to 6 hours in most patients.
_VENTOLIN _parenteral preparations are to be used under the direction
of a physician.
Increasing use of beta-
2
agonists may be a sign of worsening asthma. Under these conditions a
reassessment of the patient's therapy plan may be required and
concomitant glucocorticosteroid
therapy should be considered.
Note: The contents of the ampoules of _VENTOLIN_ Solution for